Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CD19CAR(2G)-T2A-HER2tG |
| Synonyms | |
| Therapy Description |
CD19CAR(2G)-T2A-HER2tG comprises CD4+ and CD8+ T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD19 linked to the intracellular domain of TNFRSF9 (4-1BB), CD3zeta, and a truncated form of ERBB2 (HER2), which potentially induces cytotoxic T-lymphocyte (CTL)-dependent killing of tumor cells expressing CD19 (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CD19CAR(2G)-T2A-HER2tG | CD19 Immune Cell Therapy 72 | CD19CAR(2G)-T2A-HER2tG comprises CD4+ and CD8+ T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD19 linked to the intracellular domain of TNFRSF9 (4-1BB), CD3zeta, and a truncated form of ERBB2 (HER2), which potentially induces cytotoxic T-lymphocyte (CTL)-dependent killing of tumor cells expressing CD19 (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|